Abnova Taiwan Corp - Asset Resilience Ratio

Latest as of September 2025: 0.07%

Abnova Taiwan Corp (4133) has an Asset Resilience Ratio of 0.07% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Abnova Taiwan Corp total liabilities for a breakdown of total debt and financial obligations.

Liquid Assets

NT$878.00K
≈ $27.66K USD Cash + Short-term Investments

Total Assets

NT$1.32 Billion
≈ $41.49 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2008–2022)

This chart shows how Abnova Taiwan Corp's Asset Resilience Ratio has changed over time. See 4133 net assets for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Abnova Taiwan Corp's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Abnova Taiwan Corp (4133) market capitalisation.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents NT$0.00 0%
Short-term Investments NT$878.00K 0.07%
Total Liquid Assets NT$878.00K 0.07%

Asset Resilience Insights

  • Limited Liquidity: Abnova Taiwan Corp maintains only 0.07% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Abnova Taiwan Corp Industry Peers by Asset Resilience Ratio

Compare Abnova Taiwan Corp's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Argen-X
F:1AE
Biotechnology 25.67%
Tubize-Fin
BR:TUB
Biotechnology 0.05%
BrightGene Bio Medical Technology C
SHG:688166
Biotechnology 1.00%
Dashenlin Pharm Grp Co Ltd
SHG:603233
Biotechnology 0.02%
Staidson Beijing Biopharma
SHE:300204
Biotechnology 7.93%
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
Biotechnology 41.25%
Ardelyx Inc
NASDAQ:ARDX
Biotechnology 41.14%
Xiangxue Pharmaceutical
SHE:300147
Biotechnology 0.05%

Annual Asset Resilience Ratio for Abnova Taiwan Corp (2008–2022)

The table below shows the annual Asset Resilience Ratio data for Abnova Taiwan Corp.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2022-12-31 0.06% NT$849.00K
≈ $26.75K
NT$1.37 Billion
≈ $43.31 Million
+0.02pp
2021-12-31 0.04% NT$545.00K
≈ $17.17K
NT$1.28 Billion
≈ $40.42 Million
+0.00pp
2020-12-31 0.04% NT$543.00K
≈ $17.11K
NT$1.29 Billion
≈ $40.79 Million
0.00pp
2019-12-31 0.04% NT$540.00K
≈ $17.01K
NT$1.26 Billion
≈ $39.82 Million
+0.00pp
2018-12-31 0.04% NT$537.00K
≈ $16.92K
NT$1.29 Billion
≈ $40.80 Million
+0.00pp
2017-12-31 0.04% NT$533.00K
≈ $16.79K
NT$1.30 Billion
≈ $41.08 Million
-5.50pp
2016-12-31 5.54% NT$69.11 Million
≈ $2.18 Million
NT$1.25 Billion
≈ $39.33 Million
-10.15pp
2015-12-31 15.69% NT$195.97 Million
≈ $6.17 Million
NT$1.25 Billion
≈ $39.35 Million
+15.65pp
2014-12-31 0.04% NT$522.00K
≈ $16.45K
NT$1.31 Billion
≈ $41.21 Million
0.00pp
2013-12-31 0.04% NT$517.00K
≈ $16.29K
NT$1.29 Billion
≈ $40.49 Million
+0.00pp
2012-12-31 0.04% NT$513.00K
≈ $16.16K
NT$1.29 Billion
≈ $40.71 Million
+0.00pp
2011-12-31 0.04% NT$508.00K
≈ $16.00K
NT$1.36 Billion
≈ $42.70 Million
0.00pp
2010-12-31 0.04% NT$504.00K
≈ $15.88K
NT$1.33 Billion
≈ $42.03 Million
-1.09pp
2009-12-31 1.13% NT$14.72 Million
≈ $463.73K
NT$1.31 Billion
≈ $41.13 Million
-0.07pp
2008-12-31 1.20% NT$10.26 Million
≈ $323.21K
NT$857.02 Million
≈ $27.00 Million
--
pp = percentage points

About Abnova Taiwan Corp

TW:4133 Taiwan Biotechnology
Market Cap
$41.21 Million
NT$1.31 Billion TWD
Market Cap Rank
#22591 Global
#1410 in Taiwan
Share Price
NT$21.60
Change (1 day)
-0.69%
52-Week Range
NT$21.60 - NT$33.90
All Time High
NT$149.53
About

Abnova (Taiwan) Corporation manufactures and sells various recombinant proteins and antibodies. The company's products portfolio includes SARS-CoV/CoV-2 DNA, RNA, proteins/peptides, lysates/slides, Ab pairs/kits, Ab arrays, polyclinic antibody, beads/dyes, in situ hybridization products, systems, and automations. It also offers MaxPab, monoclonal, polyclonal, recombinant, conjugate, secondary/tag… Read more